Grey Wolf gains $50m boost for antigen modulation tech

Grey Wolf Therapeutics has concluded an oversubscribed $50m in Series B financing expansion to advance its antigen modulation technology.

Related Posts

Golgi and Breye partner to develop P2X7 receptor antago...

Jul 25, 2023

Pfizer acquires ADC pioneer Seagen for $43bn

Mar 23, 2023

Risk adjusted net present value: What is the current va...

Jul 2, 2024